FOLFOX plus lenvatinib after liver transplant for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of chemotherapy (FOLFOX) and a targeted therapy (lenvatinib) can help prevent liver cancer from coming back after a liver transplant. It is for people who meet specific health and medication requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have had a liver transplant for hepatocellular carcinoma (a type of liver cancer).
- Your liver function is good (Child-Pugh class A) and you are active enough to take care of yourself (performance status 0-1).
- You are taking a specific anti-rejection medicine regimen that includes calcineurin inhibitors, mycophenolate mofetil, and sirolimus.
- Your blood counts, kidney function, and liver lab results are within an acceptable range (e.g., hemoglobin > 9 g/dL, platelets > 60, etc.).
- You can start chemotherapy and targeted therapy within 1 to 2 months after your liver transplant.
- You are not pregnant (for women), can take pills by mouth, and have no serious heart problems or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests whether taking lenvatinib (a targeted pill) before a liver procedure called TACE can help people with large hepatocellular carcinoma (HCC) get better results while waiting for a liver transplant. It may help shrink or control the cancer without stopping transplant plans.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests whether giving chemotherapy, immunotherapy, and targeted drugs before surgery helps prevent liver cancer from coming back in patients with high-risk tumors. You would receive treatment to shrink the tumor before your scheduled surgery.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.